OmniComm’s TrialMaster EDC Selected by Sorrento Therapeutics for Cancer Research


Applied Clinical Trials

Sorrento Therapeutics, Inc., a clinical stage, antibody-centric, biopharmaceutical company, has signed a new agreement with OmniComm Systems, Inc., a global provider of clinical data management technology, in which they will use OmniComm’s TrialMaster EDC technology to develop clinical studies at multiple Sorrento research sites.

Read the full release here.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.